Distinct Biological Types of Ocular Adnexal Sebaceous Carcinoma: HPV-Driven and Virus-Negative Tumors Arise through Nonoverlapping Molecular-Genetic Alterations.


Journal

Clinical cancer research : an official journal of the American Association for Cancer Research
ISSN: 1557-3265
Titre abrégé: Clin Cancer Res
Pays: United States
ID NLM: 9502500

Informations de publication

Date de publication:
15 02 2019
Historique:
received: 31 05 2018
revised: 25 07 2018
accepted: 02 11 2018
pubmed: 14 11 2018
medline: 21 4 2020
entrez: 14 11 2018
Statut: ppublish

Résumé

Ocular adnexal (OA) sebaceous carcinoma is an aggressive malignancy of the eyelid and ocular adnexa that frequently recurs and metastasizes, and effective therapies beyond surgical excision are lacking. There remains a critical need to define the molecular-genetic drivers of the disease to understand carcinomagenesis and progression and to devise novel treatment strategies. We present next-generation sequencing of a targeted panel of cancer-associated genes in 42 and whole transcriptome RNA sequencing from eight OA sebaceous carcinomas from 29 patients. We delineate two potentially distinct molecular-genetic subtypes of OA sebaceous carcinoma. The first is defined by somatic mutations impacting Together, our findings establish a potential molecular-genetic framework by which to understand the development and progression of OA sebaceous carcinoma and provide key molecular-genetic insights to direct the design of novel therapeutic interventions.

Identifiants

pubmed: 30420449
pii: 1078-0432.CCR-18-1688
doi: 10.1158/1078-0432.CCR-18-1688
doi:

Substances chimiques

RB1 protein, human 0
Receptors, Notch 0
Retinoblastoma Binding Proteins 0
TP53 protein, human 0
Tumor Suppressor Protein p53 0
Ubiquitin-Protein Ligases EC 2.3.2.27

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1280-1290

Informations de copyright

©2018 American Association for Cancer Research.

Auteurs

Michael T Tetzlaff (MT)

Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas. mtetzlaff@mdanderson.org besmaeli@mdanderson.org.
Department of Translational and Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Jonathan L Curry (JL)

Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Department of Dermatology, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Jing Ning (J)

Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Oded Sagiv (O)

Orbital Oncology and Ophthalmic Plastic Surgery, Department of Plastic Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Thomas L Kandl (TL)

Orbital Oncology and Ophthalmic Plastic Surgery, Department of Plastic Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Bo Peng (B)

Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Diana Bell (D)

Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Mark Routbort (M)

Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Courtney W Hudgens (CW)

Department of Translational and Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Doina Ivan (D)

Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Department of Dermatology, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Tae-Boom Kim (TB)

Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Ken Chen (K)

Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Agda Karina Eterovic (AK)

Sheikh Khalifa Bin Zayed Al Nahyan Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Department of Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Kenna Shaw (K)

Sheikh Khalifa Bin Zayed Al Nahyan Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Victor G Prieto (VG)

Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Department of Dermatology, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Anna Yemelyanova (A)

Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Bita Esmaeli (B)

Orbital Oncology and Ophthalmic Plastic Surgery, Department of Plastic Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas. mtetzlaff@mdanderson.org besmaeli@mdanderson.org.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH